The 2015 National Conversation on Tandem Mass Spectrometry in Newborn Screening was a two-day meeting focused on the current state of MS/MS newborn screening activities in the United States and identified and addressed challenges related to MS/MS newborn screening practices. The meeting took place on February 5-6, 2015 in Atlanta, GA.
Adenosine deaminase severe combined immunodeficiency (ADA-SCID): Christopher Haynes, PhD, Centers for Disease Control and Preventi
Hemoglobin analysis by tandem mass spectrometry: Christopher Haynes, PhD, Centers for Disease Control and Prevention
Quality Assurance & Quality Improvement: Scott Shone, PhD, New Jersey Department of Health
Newborn Screening for Guanidinoacetate Methyltransferase (GAMT) deficiency: Marzia Pasquali, PhD, FACMG, ARUP Laboratories
Second tier tests and newborn screening: Marzia Pasquali, PhD, FACMG, ARUP Laboratories
Screening for ALD Using MS/MS: Joe Orsini, PhD, New York State Department of Health
Current Thinking on Future Product Development: Mark Kuracina, PerkinElmer, Inc.
Quality Assurance for Tandem Mass Spectrometry (MS / MS) Assays in Newborn Screening: Victor De Jesús, PhD, Centers for Disease Control and Prevention
High-throughput Multiplex Newborn Screening Assay for Six Lysosomal Storage Disorders (LSDs) using Dried Blood Spots and UPLC-Tandem Mass Spectrometry: George Dizikes, PhD, Illinois Department of Public Health
Review of Results from MS/MS Pre-Conference Survey: Arthur Hagar, PhD, HCLD, Georgia Public Health Laboratory.
For more information, contact Guisou Zarbalian, MS, MPH, senior specialist, Newborn Screening and Genetics, 240.485.2736,